DICE Therapeutics, Inc.

NasdaqGM:DICE Rapporto sulle azioni

Cap. di mercato: US$2.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DICE Therapeutics Gestione

Gestione criteri di controllo 2/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

J. Judice

Amministratore delegato

US$5.8m

Compenso totale

Percentuale dello stipendio del CEO9.4%
Mandato del CEO10yrs
Proprietà del CEO1.7%
Durata media del management2.6yrs
Durata media del Consiglio di amministrazione2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

May 14
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Oct 11

Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

Sep 11
Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation

DICE Therapeutics GAAP EPS of -$0.58

Aug 11

DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs

Jul 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di J. Judice rispetto agli utili di DICE Therapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2023n/an/a

-US$104m

Mar 31 2023n/an/a

-US$91m

Dec 31 2022US$6mUS$540k

-US$84m

Sep 30 2022n/an/a

-US$77m

Jun 30 2022n/an/a

-US$74m

Mar 31 2022n/an/a

-US$59m

Dec 31 2021US$6mUS$465k

-US$49m

Sep 30 2021n/an/a

-US$40m

Jun 30 2021n/an/a

-US$29m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$637kUS$437k

-US$24m

Compensazione vs Mercato: J.'s total compensation ($USD5.77M) is about average for companies of similar size in the US market ($USD5.11M).

Compensazione vs guadagni: J.'s compensation has increased whilst the company is unprofitable.


AMMINISTRATORE DELEGATO

J. Judice (59 yo)

10yrs

Mandato

US$5,773,577

Compensazione

Dr. J. Kevin Judice, Ph D., founded DiCE Molecules SV, Inc. (formerly known as DiCE Molecules Corp). and serves as its Chief Executive Officer, President and Secretary. Dr. Judice has extensive experience...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
J. Judice
Founder10yrsUS$5.77m1.67%
$ 38.0m
Scott Robertson
Chief Business & Financial Officer5.7yrsUS$2.67m0.41%
$ 9.4m
Timothy Lu
Chief Medical Officer3yrsUS$2.72m0.32%
$ 7.2m
John Jacobsen
Chief Scientific Officer2.2yrsUS$714.79k0.31%
$ 7.0m
Mary Riley
General Counsel1.4yrsNessun datoNessun dato
Venkat Thalladi
Senior Vice President of CMC2.2yrsNessun datoNessun dato
Paul Fatheree
Senior Vice President of Medicinal Chemistryno dataNessun datoNessun dato

2.6yrs

Durata media

54yo

Età media

Gestione esperta: DICE's management team is considered experienced (2.6 years average tenure).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
J. Judice
Founderno dataUS$5.77m1.67%
$ 38.0m
Sharon Tetlow
Independent Director2.8yrsUS$264.90k0.10%
$ 2.4m
Richard Scheller
Independent Chairman of the Board7.7yrsUS$371.88k0.018%
$ 400.6k
James Scopa
Independent Director2.8yrsUS$264.90k0.086%
$ 1.9m
Mittie Doyle
Independent Director1.4yrsUS$552.51k0%
$ 0
Jake Simson
Independent Director2.7yrsUS$231.45kNessun dato
Lisa Bowers
Independent Director1.4yrsUS$552.51k0%
$ 0

2.7yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: DICE's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.